Esperion Therapeutics sale to ARCHIMED funds faces Halper Sadeh investigation

11 articles · Updated · Joplin Globe · May 1

The New York investor-rights firm said it is examining whether Esperion shareholders are being offered an unfair price in the $3.16-a-share cash deal plus contingent milestone payments.
Earlier on Thursday, ARCHIMED agreed to buy Esperion for up to $1.1 billion, including up to $100 million tied to milestones, in a transaction expected to close in the third quarter.
Esperion shares had surged 58% pre-market on the takeover news, and the acquisition would take the biotech private and remove it from Nasdaq if completed.

Is Esperion's $1.1B sale to Archimed undervaluing its true potential given analyst targets and recent financial growth?

How might Merck’s new oral PCSK9 drug reshape the cholesterol market and impact Esperion’s products and acquisition value?